rna-sci.com
mRNA Cancer Vaccine Services
mRNA cancer vaccines work by directing human cellsto produce tumor antigens, which then activatethe immune system torecognize and eliminate tumor cells Tumor antigens include the following types:
Tumor -associated antigens (TAA) : Non -mutated proteins that are overexpressed in tumor tissuesbut show low expression innormal tissues
Tumor -specific antigens (TSA): Antigens specificallyexpressed in tumor cells and absent in normal tissues,including neoantigens and oncovirus -derived antigens (HPV, HBV, and EBV) .
Sources: Cancers(Basel);FrontMicrobiol
RNASci provides Catalog Products and Custom Services formRNA cancer vaccine.
Custom Services
Structure of Multi -epitope mRNA
Pipelines: mRNA-based Cancer Vaccine
mRNA-4157
mRNA -4157 isan individualized neoantigen therapy targeting up to 34 patient-specifc tumor neoantigens, which enhances immune checkpoint inhibitorefficacyby inducing endogenous T-cellresponses .
mRNA -4157 isthe firstmRNA cancer vaccine toadvance tophase 3 clinicaltrials .
Institutions:Moderna
More Clinical Pipelines
mRNA -4157 TSA, 34 neoantigen s
3
mRNA -4106 TAA, 7 shared antigens Phase 1
BNT113
HPV E6/E7
BNT111 TAA, 4 melanoma antigens
BNT116 TAA, 6 non -mutated antigens
BNT122 TSA, neoantigen s
GRANITE/GRT -R902 * TSA, 22 neoantigen s
Phase 2/3 BioNTech
Phase 2
Phase 2
Phase 2
BioNTech
BioNTech
BioNTech
Phase 3 Gritstone
CV9104 TAA, 6 PCa antigens Phase 2 CureVac
CV9202 TAA, 6 NSCLC antigens
WGc -043 EBV a ntigen
*= self-amplifying RNA ( saRNA )
Phase 2 CureVac
Phase 1 WestGene (
Update: Jan 2026